CN107890466B - A kind of chromene lactone is used for as aristolochic acid and the purposes of the attenuation of the Chinese medicine containing aristolochic acid - Google Patents
A kind of chromene lactone is used for as aristolochic acid and the purposes of the attenuation of the Chinese medicine containing aristolochic acid Download PDFInfo
- Publication number
- CN107890466B CN107890466B CN201711263828.6A CN201711263828A CN107890466B CN 107890466 B CN107890466 B CN 107890466B CN 201711263828 A CN201711263828 A CN 201711263828A CN 107890466 B CN107890466 B CN 107890466B
- Authority
- CN
- China
- Prior art keywords
- aristolochic acid
- chromene
- chinese medicine
- chinese
- toxicity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
- A61K31/37—Coumarins, e.g. psoralen
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a kind of chromene lactones to be used for the purposes that for aristolochic acid and the Chinese medicine containing aristolochic acid is attenuated.Chromene lactone provided by the invention can reduce the renal toxicity of aristolochic acid, can be used for preparing the toxicity-reducing medicament of the single medicinal material containing aristolochic acid or Chinese medical extract or compound Chinese medicinal preparation.Above-mentioned chromene lactone can both develop into individual drug, it takes, the single medicinal material containing aristolochic acid or Chinese medical extract or Chinese medicine compound prescription and above-mentioned chromene lactone can also be developed into pharmaceutical composition simultaneously with the single medicinal material containing aristolochic acid or Chinese medical extract or compound Chinese medicinal preparation.Chinese medicine can be the Chinese medicine containing aristolochic acid such as caulis aristologhiae manshuriensis, birthwort, aristolochia fangchi, dutchmanspipe root, Ciliatenerve Knotweed Root, berba aristolochiae mollissimae, herba aristolochiae, Cortex Magnoliae Officinalis, asarum.Chinese medicine compound prescription can be the Chinese medicine compound prescriptions containing aristolochic acid such as rheum officinale clearing stomach ball, children-welfare tablet, Fenqing Wulin pill, Longdan Xiegan wan, shixiang fansheng pill, storax pill for treating coronary heart disease.
Description
Technical field
The invention belongs to field of medicaments, are related to chromene lactone for aristolochic acid and the Chinese medicine containing aristolochic acid is attenuated
Purposes.
Background technique
On October 18th, 2017, the researcher from Singapore and TaiWan, China print Science in Science
Translational Medicine issues entitled " Aristolochic acids and their derivatives are
The research paper of widely implicated in liver cancers in Taiwan and throughoutAsia ".It should
Article points out dark aspect (toxic side effect) of Chinese herbal medicine, leading role-aristolochic acid in the form of cover story
(aristolochic acids, AA) is a kind of chemistry being widely present in aristolochiaceae plant and a variety of natural herbals at
Point.The chemical structure of four kinds of main aristolochic acids is as follows:
The toxicity that state food pharmaceuticals administration general bureau of China (CFDA) and the world of medicine also pay special attention to aristolochic acid is made
With.The work that standardized administration contains Aristolochic Acid compound Chinese herbal medicine is unfolded already in China, and is continued for carrying out.It is early
The case of acute renal failure has been caused to be reported (reference excessive use Aristolochiaceae caulis aristologhiae manshuriensis in Wu Han pine in 1964
Document: Wu Songhan, caulis akebiae induced Acute renal failure two reports, Jiangsu traditional Chinese medicine, 1964).In the 1990s, " ratio
The generation of the events such as slimming drugs (aristolochia fangchi) when sharp ", " Longdan Xiegan wan ", and Chinese patent drug containing aristolochic acid cause kidney function energy loss
Harmful case quantity is also increasing, promote the toxicity research of the Chinese herbal medicine containing aristolochic acid further deeply, manage it is stringenter.
It has been carried out under version " Chinese Pharmacopoeia " caulis aristologhiae manshuriensis kinds in 2000 using limiting, indicating in the case where paying attention to item " can not be mostly used, long term usage；Kidney
Insufficiency and be not taken by pregnant women "；CFDA eliminated in 2003 the medicinal standard of caulis aristologhiae manshuriensis, 2004 but eliminate aristolochia fangchi and
The medicinal standard of dutchmanspipe root, and propose to reinforce the supervision pipe of the Chinese materia medica preparation containing birthwort, berba aristolochiae mollissimae, herba aristolochiae and Ciliatenerve Knotweed Root
Reason；2005 version " Chinese Pharmacopoeia " also start to phase out the Chinese herbal medicine containing aristolochic acid in record, until version " China in 2015
Pharmacopeia " only 3 kinds of herba aristolochiae, birthwort and asarum drugs containing aristolochic acid still record wherein.
But have much that the Chinese medicine containing aristolochic acid in tcm field has its special purposes, and do not have also at present
There is the side's of the entering substitute for searching out these Chinese medicines containing aristolochic acid.This results in some to pass through the allusion of succession in hundreds and thousands of years
Recipe cannot be further continued for using tangible sorry because of the renal toxicity of aristolochic acid.
Summary of the invention
It is used to be aristolochic acid it is an object of the invention to overcome the deficiencies of the prior art and provide a kind of chromene lactone
And the purposes of the Chinese medicine attenuation containing aristolochic acid, with the renal toxicity for reducing the Chinese medicine containing aristolochic acid.
Above-mentioned purpose of the invention is achieved by following technical solution:
The chromene lactone of following chemical structure is used to prepare the purposes of aristolochic acid toxicity-reducing medicament:
Preferably, the attenuation refers to the renal toxicity for reducing aristolochic acid.
Preferably, the aristolochic acid is Aristolochic acid-I, Aristolochic acid-I I, Aristolochic acid-I II and Aristolochic acid-I V
One of or it is a variety of.
Above-mentioned chromene lactone is used to prepare the purposes of the toxicity-reducing medicament of the single medicinal material containing aristolochic acid；It is described to subtract
Poison refers to the renal toxicity for reducing the single medicinal material containing aristolochic acid.
Above-mentioned chromene lactone is used to prepare the purposes of the toxicity-reducing medicament of the Chinese medical extract containing aristolochic acid；It is described
Attenuation refers to the renal toxicity for reducing the Chinese medical extract containing aristolochic acid.
Preferably, the Chinese medicine is caulis aristologhiae manshuriensis, birthwort, aristolochia fangchi, dutchmanspipe root, Ciliatenerve Knotweed Root, berba aristolochiae mollissimae, herba aristolochiae, thickness
Piao, asarum etc..
Above-mentioned chromene lactone is used to prepare the purposes of the toxicity-reducing medicament of the compound Chinese medicinal preparation containing aristolochic acid；Institute
It states attenuation and refers to the renal toxicity for reducing the compound Chinese medicinal preparation containing aristolochic acid.
Preferably, the compound Chinese medicinal preparation be rheum officinale clearing stomach ball, children-welfare tablet, Fenqing Wulin pill, Longdan Xiegan wan,
Shixiang fansheng pill, storax pill for treating coronary heart disease etc..
A kind of pharmaceutical composition further includes including the single medicinal material containing aristolochic acid, Chinese medical extract or Chinese medicine compound prescription
Above-mentioned chromene lactone.
Advantages of the present invention:
It is a discovery of the invention that chromene lactone provided by the invention can reduce the renal toxicity of aristolochic acid, can be used for
Prepare the toxicity-reducing medicament of the single medicinal material containing aristolochic acid or Chinese medical extract or compound Chinese medicinal preparation.In above-mentioned chromene
Ester can both develop into individual drug, with containing aristolochic acid single medicinal material or Chinese medical extract or compound Chinese medicinal preparation simultaneously
Take, can also by containing aristolochic acid single medicinal material or Chinese medical extract or Chinese medicine compound prescription and above-mentioned chromene lactone develop at
Pharmaceutical composition.
Detailed description of the invention
Fig. 1 is each group HK-2 Apoptosis ratio (%)；
Fig. 2 is that each group renal interstitial fibrosis rat relative area compares；
Fig. 3 is the relative expression levels of each group renal tissues of rats markers of fibrosis PROTEIN C OL- I.
Specific embodiment
It is specific with reference to the accompanying drawings and examples to introduce essentiality content of the present invention, but guarantor of the invention is not limited with this
Protect range.
The chromene lactone that following embodiments use is the compound such as flowering structure, and purchase or self-control, purity are not less than
95%.
Embodiment 1: the protective effect for causing people's renal cells to damage aristolochic acid
One, experimental material
People's kidney proximal tubular cell line (HK-2) is purchased from China typical culture collection center；
Aristolochic acid-I (AA- I) is purchased from Nat'l Pharmaceutical & Biological Products Control Institute；
Fetal calf serum (FCS), Gibico company；DMEM:HamsF-12 culture medium (Hyclone)；Annexin-V reagent
Box, Invitrogen company；
Enzyme-linked immunosorbent assay instrument, Thermo fisher company of the U.S.；Flow cytometer, U.S. company BD.
Two, experimental method
1, cell culture and grouping
Well-grown HK-2 cell is taken, is suspended in containing 10%FCS and 1% penicillin+streptomysin DMEM:HamsF-12
In culture medium, with 6 × 107/ L cell suspension inoculation is in 96 orifice plates, and every hole is inoculated with 100 μ L, in 37 DEG C, 5%CO2, humidity
Cultivated under 100% environment after cell is adherent for 24 hours, inhale and abandon culture solution, by it is following be separately added into relative medicine and continue to be incubated for train
Support 48h.6 groups are set up in experiment altogether, and each group sets 8 multiple holes:
(1) control group: AA- I is not added in culture solution；
(2) AA- I aristolochic acid group: is added in culture solution (25mg/L, each pharmaceutical intervention group are same)；
(3) netvein goldenray root element A (10mg/L is final concentration, similarly hereinafter) and AA- I netvein goldenray root element A group: is added in culture solution simultaneously；
(4) netvein goldenray root element B (10mg/L) and AA- I netvein goldenray root element B group: is added in culture solution simultaneously；
(5) netvein goldenray root element C (10mg/L) and AA- I netvein goldenray root element C group: is added simultaneously in culture solution；
(6) netvein goldenray root plain (10mg/L) and AA- I netvein goldenray root element group: is added simultaneously in culture solution；
2, mtt assay measures cell survival rate
Each group 4h before culture terminates, the 20 μ L of MTT solution of 5mg/L is added in every hole, and after culture, 100 μ are added in every hole
L DMSO, using the OD value for measuring each hole at enzyme-linked immunosorbent assay instrument 480nm.
3, flow cytometry detects apoptosis rate
After culture, cell 1 × 10 is collected6A/mL, 1000rpm are centrifuged 5min, abandon supernatant, and cell is resuspended with PBS,
It is operated according to Annexin-VFITC cell apoptosis detection kit specification, detects the percentage of apoptotic cell and non-viable non-apoptotic cell.
4, statistical method
It is analyzed using 19.0 software statistics of SPSS, data are indicated with mean value ± deviation, and comparison among groups use single factor test variance
Analysis.
Three, experimental result
1, mtt assay measures cell survival rate
Compared with the control group, after AA- I acts on 48h, aristolochic acid group HK-2 cell activity is obvious suppressed (P < 0.05)；
Compared with aristolochic acid group, netvein goldenray root element A group, netvein goldenray root element B group, netvein goldenray root element C group, netvein goldenray root element group HK-2 cell activity are equal
Significantly improve (P < 0.05).OD value under the conditions of each group 480nm wavelength detecting is shown in Table 1.
OD value under the conditions of 1 each group 480nm wavelength detecting of table
2, flow cytometry detects apoptosis rate
Compared with the control group, after AA- I acts on 48h, aristolochic acid group HK-2 Apoptosis ratio obviously increases (P <
0.05)；Compared with aristolochic acid group, netvein goldenray root element A group, netvein goldenray root element B group, netvein goldenray root element C group, netvein goldenray root element group HK-2 cell
Apoptosis ratio is substantially reduced (P < 0.05).Each group apoptosis value is shown in Table 2 and Fig. 1.
2 each group HK-2 Apoptosis ratio of table
Embodiment explanation, Aristolochic Acid in Antagonizing Human Renal Tubular epithelial cell HK-2 have apparent cytotoxicity, will cause
HK-2 survival rate reduces, apoptosis rate increases；Chromene lactone compound netvein goldenray root element A provided by the invention, netvein goldenray root element B,
Netvein goldenray root element C, netvein goldenray root element can with the cytotoxicity of antagonism Aristolochic Acid in Antagonizing Human Renal Tubular epithelial cell HK-2, have exploitation at
The prospect of aristolochic acid toxicity-reducing medicament.
Embodiment 2: lead to the protective effect of renal interstitial fibrosis rat to aristolochic acid
One, experimental material
SPF grades of male SD rats, weight 280-300g are purchased from Jiangning county Qinglongshan animal reproduction field；
3,4-methylenedioxy-8-methoxy-10-nitro-1-phenanthrenecarboxylic acid is dissolved with edible oil, as stomach-filling working solution.
Two, experimental method
1, aristolochic acid kidney fibrosis rat model and experimental group are established
Aristolochic acid kidney fibrosis modeling method (bibliography: the foundation of Chronic Aristolochic Acid Nephropathy animal model and ox
Sulfonic acid acts on its early protection, Chinese combination of Chinese tradiational and Western medicine magazine in June, 2003 fundamental research spy collection of volume 23, and Beijing is big
Study medicine department of pathology of the department of the Chinese Academy of Sciences): first by rat by dosage the continuous gavage 5d, drug withdrawal 9d of 20mg/kg/d 3,4-methylenedioxy-8-methoxy-10-nitro-1-phenanthrenecarboxylic acid；Hereafter agent
Amount reduces to 15mg/kg/d, every other week gastric infusion, until the 11st week.
After a week by SPF grades of male SD rat adaptable feds, 6 groups, every group 10 are randomly divided into according to weight:
(1) control group: isometric solvent (edible oil) is given in stomach-filling；
(2) aristolochic acid group: modeling according to the method described above；
(3) netvein goldenray root element A group: modeling according to the above method, and stomach-filling 25mg/kg/d netvein goldenray root element A the next day from first week；
(4) netvein goldenray root element B group: modeling according to the above method, and stomach-filling 25mg/kg/d netvein goldenray root element B the next day from first week；
(5) netvein goldenray root element C group: modeling according to the above method, and stomach-filling 25mg/kg/d netvein goldenray root element C the next day from first week；
(6) netvein goldenray root element group: modeling according to the above method, and stomach-filling 25mg/kg/d netvein goldenray root element the next day from first week；
2, renal fibrosis pathologic finding
After culture, put to death rat, take out rat kidney, PBS buffer solution elute completely on ice, it is conventional be dehydrated, embed,
After slice and Masson dyeing, optical microscopy (× 100) acquires renal interstitial image (every rat random acquisition of cortical section
15 visuals field), automatic measurement point is carried out with multi-functional true color pathological image analysis system (BJ University of Aeronautics & Astronautics manufactures)
Analysis, the kidney region fibrosis relative area=area the renal interstitial Lv Ran area/visual field gross area × 100%.
3, the detection that renal fibrosis marker protein COL- I is expressed
After culture, rat is put to death, rat kidney is taken out, is placed on ice, prevents protein degradation.Clip about 35mg
Tissue is added the lysate that 350 μ L concentration are 100mg/mL, is fully ground with grinding rod, stands 20min on ice, opposite at 4 DEG C
Centrifugal force 5.67 × 104× g is centrifuged 15min.Protein supernatant is drawn, precipitating is discarded.Relative centrifugal force 5.67 × 10 at 4 DEG C4
× g is centrifuged 15min, draws protein supernatant again, discards precipitating.Using GAPDH albumen as internal reference, using immunoblotting
The relative expression levels of (western blot) measurement each group renal tissues of rats COL- I.
4, statistical method
It is analyzed using 19.0 software statistics of SPSS, data are indicated with mean value ± deviation, and comparison among groups use single factor test variance
Analysis.
Three, experimental result
1, each group renal interstitial fibrosis rat relative area
Compared with the control group, aristolochic acid group renal interstitial fibrosis rat relative area significantly increases (P < 0.05)；With horse
Pocket bell acid group compares, netvein goldenray root element A group, netvein goldenray root element B group, netvein goldenray root element C group, netvein goldenray root element group renal interstitial fibrosis rat phase
(P < 0.05) is substantially reduced to area.Each group renal interstitial fibrosis rat relative area is shown in Table 3 and Fig. 2.
3 renal interstitial fibrosis rat relative area (%) of table
2, I expression of each group renal tissues of rats markers of fibrosis PROTEIN C OL-
Compared with the control group, I protein expression level of COL- significantly increases (P < in aristolochic acid group renal tissues of rats
0.05)；Compared with aristolochic acid group, netvein goldenray root element A group, netvein goldenray root element B group, netvein goldenray root element C group, netvein goldenray root element group Rat renal group
It knits middle I protein expression level of COL- and is substantially reduced (P < 0.05).Relative expression levels such as Fig. 3 institute of each group rat COL- I
Show.
Embodiment explanation, aristolochic acid will cause renal tissues of rats fibrosis；Chromene lactone provided by the invention
Compound netvein goldenray root element A, netvein goldenray root element B, netvein goldenray root element C, netvein goldenray root element can have with the internal renal toxicity of antagonism aristolochic acid
Develop into the prospect of aristolochic acid toxicity-reducing medicament.
Embodiment 3: pharmaceutical composition is made with single medicinal material
A kind of pharmaceutical composition, be single medicinal material and netvein goldenray root element A, netvein goldenray root element B, netvein goldenray root element C, in netvein goldenray root element
One or more combinations；The single medicinal material can be caulis aristologhiae manshuriensis, birthwort, aristolochia fangchi, dutchmanspipe root, Ciliatenerve Knotweed Root, berba aristolochiae mollissimae, day
The Chinese medicine containing aristolochic acid such as celestial rattan, Cortex Magnoliae Officinalis, asarum.
Embodiment 4: pharmaceutical composition is made with Chinese medical extract
A kind of pharmaceutical composition, be Chinese medical extract and netvein goldenray root element A, netvein goldenray root element B, netvein goldenray root element C, in netvein goldenray root element
One or more combinations；The Chinese medicine can be caulis aristologhiae manshuriensis, birthwort, aristolochia fangchi, dutchmanspipe root, Ciliatenerve Knotweed Root, berba aristolochiae mollissimae, beauty
The Chinese medicine containing aristolochic acid such as rattan, Cortex Magnoliae Officinalis, asarum.
The pharmaceutical composition can be used for pharmacy or the products such as slim tea be made into.
Embodiment 5: pharmaceutical composition is made with Chinese medicine compound prescription
A kind of pharmaceutical composition, be Chinese medicine compound prescription and netvein goldenray root element A, netvein goldenray root element B, netvein goldenray root element C, in netvein goldenray root element
One or more combinations；The Chinese medicine compound prescription can be rheum officinale clearing stomach ball, children-welfare tablet, Fenqing Wulin pill, Longdan Xiegan wan,
The Chinese medicine compound prescription containing aristolochic acid such as shixiang fansheng pill, storax pill for treating coronary heart disease.
To sum up, chromene lactone provided by the invention can reduce the renal toxicity of aristolochic acid, can be used for preparation and contain
There are the single medicinal material of aristolochic acid or the toxicity-reducing medicament of Chinese medical extract or compound Chinese medicinal preparation.Above-mentioned chromene lactone both may be used
To develop into individual drug, taken simultaneously with the single medicinal material containing aristolochic acid or Chinese medical extract or compound Chinese medicinal preparation
With the single medicinal material containing aristolochic acid or Chinese medical extract or Chinese medicine compound prescription and above-mentioned chromene lactone can also being developed
At pharmaceutical composition.
The effect of above-described embodiment is specifically to introduce essentiality content of the invention, but those skilled in the art should know
Protection scope of the present invention should not be confined to the specific embodiment by road.
Claims (8)
1. the chromene lactone of following chemical structure is used to prepare the purposes of aristolochic acid toxicity-reducing medicament:
2. purposes according to claim 1, it is characterised in that: the attenuation refers to the renal toxicity for reducing aristolochic acid.
3. purposes according to claim 2, it is characterised in that: the aristolochic acid is Aristolochic acid-I, aristolochic acid-
II, Aristolochic acid-I II or Aristolochic acid-I V.
4. the use that chromene lactone described in claim 1 is used to prepare the toxicity-reducing medicament of the single medicinal material containing aristolochic acid
On the way；The attenuation refers to the renal toxicity for reducing the single medicinal material containing aristolochic acid.
5. chromene lactone described in claim 1 is used to prepare the toxicity-reducing medicament of the Chinese medical extract containing aristolochic acid
Purposes；The attenuation refers to the renal toxicity for reducing the Chinese medical extract containing aristolochic acid.
6. purposes according to claim 4 or 5, it is characterised in that: the Chinese medicine is caulis aristologhiae manshuriensis, birthwort, aristolochia fangchi, blueness
Radix aucklandiae, Ciliatenerve Knotweed Root, berba aristolochiae mollissimae, herba aristolochiae, Cortex Magnoliae Officinalis or asarum.
7. the toxicity-reducing medicament that chromene lactone described in claim 1 is used to prepare the compound Chinese medicinal preparation containing aristolochic acid
Purposes；The attenuation refers to the renal toxicity for reducing the compound Chinese medicinal preparation containing aristolochic acid.
8. purposes according to claim 7, it is characterised in that: the compound Chinese medicinal preparation is rheum officinale clearing stomach ball, little Er Jin
Red piece, Fenqing Wulin pill, Longdan Xiegan wan, shixiang fansheng pill or storax pill for treating coronary heart disease.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711263828.6A CN107890466B (en) | 2017-12-05 | 2017-12-05 | A kind of chromene lactone is used for as aristolochic acid and the purposes of the attenuation of the Chinese medicine containing aristolochic acid |
| PCT/CN2018/084057 WO2019109576A1 (en) | 2017-12-05 | 2018-04-23 | Use of benzopyran compound |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711263828.6A CN107890466B (en) | 2017-12-05 | 2017-12-05 | A kind of chromene lactone is used for as aristolochic acid and the purposes of the attenuation of the Chinese medicine containing aristolochic acid |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN107890466A CN107890466A (en) | 2018-04-10 |
| CN107890466B true CN107890466B (en) | 2018-12-21 |
Family
ID=61806950
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711263828.6A Active CN107890466B (en) | 2017-12-05 | 2017-12-05 | A kind of chromene lactone is used for as aristolochic acid and the purposes of the attenuation of the Chinese medicine containing aristolochic acid |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107890466B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019109576A1 (en) * | 2017-12-05 | 2019-06-13 | 赵腾骅 | Use of benzopyran compound |
| CN107987089B (en) * | 2017-12-06 | 2018-09-04 | 南京道尔医药科技有限公司 | A kind of extract, preparation method and medical usage rich in chromene lactone |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103083434A (en) * | 2013-02-22 | 2013-05-08 | 上海市普陀区中心医院 | Yang warming and blood activating traditional Chinese compound preparation for preventing and treating chronic kidney diseases and application thereof |
| CN104142384A (en) * | 2014-08-01 | 2014-11-12 | 山东省科学院生物研究所 | Method for screening active compounds capable of protecting or improving renal functions |
-
2017
- 2017-12-05 CN CN201711263828.6A patent/CN107890466B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103083434A (en) * | 2013-02-22 | 2013-05-08 | 上海市普陀区中心医院 | Yang warming and blood activating traditional Chinese compound preparation for preventing and treating chronic kidney diseases and application thereof |
| CN104142384A (en) * | 2014-08-01 | 2014-11-12 | 山东省科学院生物研究所 | Method for screening active compounds capable of protecting or improving renal functions |
Non-Patent Citations (5)
| Title |
|---|
| 中药马兜铃酸的肾毒性研究;李文婷等;《世界科学技术—中医药现代化》;20151231;第17卷(第5期);1095-1099 * |
| 岩天麻化学成分的研究（1）;赵树年等;《中草药》;19821231;第13卷(第3期);12 * |
| 岩天麻化学成分的研究II;陈于澍等;《中草药》;19851231;第16卷(第6期);277-278 * |
| 氘代苯并吡喃类化合物合成及其应用;张艳梅等;《2012年中国药学大会暨第十二届中国药师周论文集》;20121231;1-23 * |
| 马兜铃酸肾毒性的研究进展;彭金玲等;《环球中医药》;20130131;第6卷(第1期);59-65 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN107890466A (en) | 2018-04-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20160136224A1 (en) | Method for preparing a camellia nitidissima chi lipid-lowering and hypoglycemic agent | |
| CN104189099A (en) | Application of cistanche phenylethanoid glycoside extractive to control altitude sickness | |
| CN107890466B (en) | A kind of chromene lactone is used for as aristolochic acid and the purposes of the attenuation of the Chinese medicine containing aristolochic acid | |
| Jiang et al. | Total alkaloids of Tripterygium hypoglaucum (levl.) Hutch inhibits tumor growth both in vitro and in vivo | |
| CN107987089B (en) | A kind of extract, preparation method and medical usage rich in chromene lactone | |
| CN101444549A (en) | Composition of plant extracts for preventing or curing metabolism disorder of blood lipid and application thereof | |
| Wang et al. | Effects of dihydroartemisinin, a metabolite of artemisinin, on colon cancer chemoprevention and adaptive immune regulation | |
| CN107951880B (en) | A kind of benzopyrone is used for as aristolochic acid and the purposes of the attenuation of the Chinese medicine containing aristolochic acid | |
| Zakaria et al. | Anti-uterine fibroid effect of standardized labisia pumila var. Alata extracts in vitro and in human uterine fibroid cancer xenograft model | |
| CN1883566B (en) | Anti-inflammation medicine and method for preparing same | |
| CN105878233B (en) | Application of the artemisinin derivative in preparation treatment hepatic fibrosis medicines | |
| CN107753480A (en) | Application of the Praeruptorin D in drug induced hepatic injury protection medicine is prepared | |
| CN103356812B (en) | A kind of Radix Wikstroemae granule | |
| LI et al. | Screening of phytoestrogenic effective extracts and dose of Cistanche deserticola | |
| CN108042527A (en) | Purposes of the Praeruptorin B in drug induced hepatic injury protection drug is prepared | |
| CN105663150B (en) | A kind of application of phenylpropanoids and its pharmaceutically acceptable salt in the drug for preparing treatment diseases associated with inflammation | |
| Cherian et al. | Therapeutically important bioactive compounds of the genus Polygonum L. and their possible interventions in clinical medicine | |
| CN108030781A (en) | Purposes of the Isomperatorin in drug induced hepatic injury protection medicine is prepared | |
| CN105708845B (en) | A kind of application of phenylpropanoids and its pharmaceutically acceptable salt in the drug for preparing treatment diseases associated with inflammation | |
| CN104127544B (en) | The application in preparing medicine of Murraya tetramera Huang and extract thereof | |
| CN109550035A (en) | A kind of new application of Chinese medicine composition in preparation antidepressant | |
| CN103721176B (en) | Chinese medicine preparation for the treatment of breast cancer relapse transfer and preparation method thereof | |
| CN103816392B (en) | Pharmaceutical composition of a kind for the treatment of organs fibrosis and its production and use | |
| Nguyena et al. | Subacute oral toxicity evaluation of the ethanolic extract of Hydnophytum formicarum Jack. tubers in Phu Quoc, Vietnam | |
| CN103356813B (en) | Indian stringbush root capsule |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20181107 Address after: 322105 No. 1, Shi Tan Village, Ge Shan town, Dongyang, Jinhua, Zhejiang Applicant after: Dongyang Xinyi industrial product design Co., Ltd. Address before: 210009 China Medicine University, 639 Jiangning dragon road, Jiangning, Nanjing. Applicant before: Zhao Tenghua |
|
| TA01 | Transfer of patent application right | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20210929 Address after: 264200 No. 4, Huihe Road, Yangting Town, Huancui District, Weihai City, Shandong Province Patentee after: Weihai Huayang Pharmaceutical Co.,Ltd. Address before: 322105 No. 1, Shi Tan Village, Ge Shan town, Dongyang, Jinhua, Zhejiang Patentee before: DONGYANG XINYI INDUSTRIAL PRODUCT DESIGN Co.,Ltd. |
|
| TR01 | Transfer of patent right |